Get started
Author

T Witthöft

Observed names: T. Witthoft, T. Witthöft, T. Witthöft, Th. Witthöft
OpenAlex ID: A5108567167
Apoptosis of human intestinal epithelial cells after bacterial invasion.
1998 · J M Kim, L Eckmann, et al. · Journal of Clinical Investigation · 309
PDF
The TCR-δ repertoire in human intestine undergoes characteristic changes during fetal to adult development
1997 · W Holtmeier, T Witthöft, et al. · The Journal of Immunology · 61
Safety, tolerability and efficacy of peginterferon alpha‐2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial
2007 · Th. Witthöft, B. Möller, et al. · Journal of Viral Hepatitis · 56
PDF
Enhanced Human β-Defensin-2 (hBD-2) Expression by Corticosteroids Is Independent of NF-κB in Colonic Epithelial Cells (CaCo2)
2005 · T. Witthöft, C. S. Pilz, et al. · Digestive Diseases and Sciences · 34
Massive Lungenembolie nach endoskopischer Therapie einer Fundusvarizenblutung
2004 · T. Witthöft, N. Homann, et al. · Zeitschrift für Gastroenterologie · 5
Sustained responders have lower rates of liver-related events and a better quality of life and productivity compared with non-responders/relapsers after antiviral treatment of chronic hepatitis C
2013 · S Mauss, J Petersen, et al. · Zeitschrift für Gastroenterologie · 3
Sustained virologic responders have lower rates of liver-related events and a better quality of life and productivity compared with non-responders/relapsers after antiviral treatment of chronic hepatitis C
2012 · S Mauss, J Petersen, et al. · Zeitschrift für Gastroenterologie · 2
Daily consensus interferon versus peg-interferon alfa2b with weight based ribavirin in treatment-naive patients with chronic hepatitis C serotype-1
2007 · M Schuchmann, H Löhr, et al. · Zeitschrift für Gastroenterologie · 2
Patient adherence: The influence of non-virological factors in a real world setting
2013 · T Witthöft, R Link, et al. · Zeitschrift für Gastroenterologie · 1
1164 Hemoglobine Decline During Peginterferon Alfa-2b/ribavirin Treatment in Real-life Is Associated With Favorable Svr Rates in Difficult-to-treat Patients With Hcv Genotype 1 Infection
2012 · G. Teuber, S. Mauss, et al. · Journal of Hepatology · 1
Behandlung der chronischen Hepatitis C (cHC) mit PegInterferon alfa 2b und Ribavirin bei HIV oder HBV koinfizierten Patienten
2008 · S Mauss, D Hueppe, et al. · Zeitschrift für Gastroenterologie · 1
Low frequency of drug-drug interactions (DDIs) with the novel all oral antivirals elbasvir (EBV) and grazoprevir (GRZ) in patients with HCV genotype 1 infection in German real-world
2016 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Boceprevir triple therapy of chronic HCV genotype 1 (G1) infection in previously untreated patients: Efficacy, predictability of virologic response and safety in German real-life
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Treatment of chronic HCV Genotype 1 infection with Boceprevir in German real-life:The impact of SVR on initially elevated and initially normal serum alanine aminotransferase (ALT) and gamma-glutamyl transpeptidase (GGT) levels
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Pre-existing co-morbidities and co-medications of patients undergoing treatment of chronic HCV G1 infection in German real-life
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Efficacy and safety of Boceprevir triple therapy in previously treated patients with HCV Genotype 1 (G1) infection in German real-life
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Gender- and age-related co-morbidities of patients undergoing treatment of chronic HCV G1 infection in German real-life
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Serum gamma-glutamyl transferase (GGT) levels within the normal range are associated with a high SVR rate of 85% in treatment-naive patients undergoing Boceprevir triple therapy for HCV genotype 1 (G1) infection in German real-world
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Boceprevir triple therapy of HCV genotype 1 (G1) infection in German real-life: comparable high SVR rates up to 87% in treatment-naïve and previously treated patients who achieve an early virologic response
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Current evaluation of the patient with chronic HCV genotype 1 infection before antiviral treatment in German routine clinical practice
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Gender-dependent differences in the efficacy and safety of Boceprevir triple therapy in German real-life
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Current clinical evaluation of the patient with HCV genotype 1 infection before antiviral treatment in German routine clinical practice
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Baseline gamma-GT levels within the normal range predict high virologic response rates in treatment-naïve patients undergoing boceprevir triple therapy for HCV genotype 1 (G1) infection
2015 · P Buggisch, HF Löhr, et al. · Zeitschrift für Gastroenterologie
Treatment of previously untreated patients with chronic HCV genotype 1 infection with boceprevir in German real-life: high end of treatment response of 95% in patients with early virologic response
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Baseline predictors of an early virologic response (EVR) in previously untreated patients undergoing boceprevir (BOC) triple therapy for HCV genotype 1 infection in German real-life
2015 · P Buggisch, H Löhr, et al. · Zeitschrift für Gastroenterologie
Works count: 60
Citation count: 475
H-index: 5
I10-index: 4
Year
Topic
Type